PCS Table 3E0

Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach

Introduction of Oxazolidinones into Skin and Mucous Membranes, External Approach

Introduction of Other Anti-infective into Skin and Mucous Membranes, External Approach

Introduction of Anti-inflammatory into Skin and Mucous Membranes, External Approach

Introduction of Serum, Toxoid and Vaccine into Skin and Mucous Membranes, External Approach

Introduction of Anesthetic Agent into Skin and Mucous Membranes, External Approach

Introduction of Other Therapeutic Substance into Skin and Mucous Membranes, External Approach

Introduction of Other Diagnostic Substance into Skin and Mucous Membranes, External Approach

Introduction of Pigment into Skin and Mucous Membranes, External Approach

Introduction of Analgesics, Hypnotics, Sedatives into Skin and Mucous Membranes, External Approach

Introduction of Destructive Agent into Skin and Mucous Membranes, External Approach

Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Open Approach

Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach

Introduction of Oxazolidinones into Subcutaneous Tissue, Percutaneous Approach

Introduction of Other Anti-infective into Subcutaneous Tissue, Percutaneous Approach

Introduction of Anti-Infective Envelope into Subcutaneous Tissue, Percutaneous Approach

Introduction of Anti-inflammatory into Subcutaneous Tissue, Percutaneous Approach

Introduction of Influenza Vaccine into Subcutaneous Tissue, Percutaneous Approach

Introduction of Serum, Toxoid and Vaccine into Subcutaneous Tissue, Percutaneous Approach

Introduction of Nutritional Substance into Subcutaneous Tissue, Percutaneous Approach

Introduction of Electrolytic and Water Balance Substance into Subcutaneous Tissue, Percutaneous Approach

Introduction of Anesthetic Agent into Subcutaneous Tissue, Percutaneous Approach

Introduction of Other Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach

Introduction of Radioactive Substance into Subcutaneous Tissue, Percutaneous Approach

Introduction of Other Diagnostic Substance into Subcutaneous Tissue, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Subcutaneous Tissue, Percutaneous Approach

Introduction of Destructive Agent into Subcutaneous Tissue, Percutaneous Approach

Introduction of Insulin into Subcutaneous Tissue, Percutaneous Approach

Introduction of Other Hormone into Subcutaneous Tissue, Percutaneous Approach

Introduction of Other Antineoplastic into Muscle, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach

Introduction of Oxazolidinones into Muscle, Percutaneous Approach

Introduction of Other Anti-infective into Muscle, Percutaneous Approach

Introduction of Anti-inflammatory into Muscle, Percutaneous Approach

Introduction of Influenza Vaccine into Muscle, Percutaneous Approach

Introduction of Serum, Toxoid and Vaccine into Muscle, Percutaneous Approach

Introduction of Nutritional Substance into Muscle, Percutaneous Approach

Introduction of Electrolytic and Water Balance Substance into Muscle, Percutaneous Approach

Introduction of Anesthetic Agent into Muscle, Percutaneous Approach

Introduction of Other Therapeutic Substance into Muscle, Percutaneous Approach

Introduction of Radioactive Substance into Muscle, Percutaneous Approach

Introduction of Other Diagnostic Substance into Muscle, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Muscle, Percutaneous Approach

Introduction of Destructive Agent into Muscle, Percutaneous Approach

Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach

Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach

Introduction of Other Antineoplastic into Peripheral Vein, Open Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach

Introduction of Clofarabine into Peripheral Vein, Open Approach

Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Open

Introduction of Other Thrombolytic into Peripheral Vein, Open Approach

Introduction of Oxazolidinones into Peripheral Vein, Open Approach

Introduction of Other Anti-infective into Peripheral Vein, Open Approach

Introduction of Anti-inflammatory into Peripheral Vein, Open Approach

Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Open Approach

Introduction of Nutritional Substance into Peripheral Vein, Open Approach

Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Open Approach

Introduction of Intracirculatory Anesthetic into Peripheral Vein, Open Approach

Introduction of Other Therapeutic Substance into Peripheral Vein, Open Approach

Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Open Approach

Introduction of Radioactive Substance into Peripheral Vein, Open Approach

Introduction of Other Diagnostic Substance into Peripheral Vein, Open Approach

Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Open Approach

Introduction of Platelet Inhibitor into Peripheral Vein, Open Approach

Introduction of Antiarrhythmic into Peripheral Vein, Open Approach

Introduction of Destructive Agent into Peripheral Vein, Open Approach

Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Open Approach

Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Open Approach

Introduction of Insulin into Peripheral Vein, Open Approach

Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Open Approach

Introduction of Other Hormone into Peripheral Vein, Open Approach

Introduction of Immunostimulator into Peripheral Vein, Open

Introduction of Immunosuppressive into Peripheral Vein, Open

Introduction of Vasopressor into Peripheral Vein, Open Approach

Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach

Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach

Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach

Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach

Introduction of Recombinant Human-activated Protein C into Peripheral Vein, Percutaneous

Introduction of Other Thrombolytic into Peripheral Vein, Percutaneous Approach

Introduction of Oxazolidinones into Peripheral Vein, Percutaneous Approach

Introduction of Other Anti-infective into Peripheral Vein, Percutaneous Approach

Introduction of Anti-inflammatory into Peripheral Vein, Percutaneous Approach

Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Percutaneous Approach

Introduction of Nutritional Substance into Peripheral Vein, Percutaneous Approach

Introduction of Electrolytic and Water Balance Substance into Peripheral Vein, Percutaneous Approach

Introduction of Embryonic Stem Cells into Peripheral Vein, Percutaneous Approach

Introduction of Intracirculatory Anesthetic into Peripheral Vein, Percutaneous Approach

Introduction of Other Therapeutic Substance into Peripheral Vein, Percutaneous Approach

Introduction of Blood Brain Barrier Disruption Substance into Peripheral Vein, Percutaneous Approach

Introduction of Glucarpidase into Peripheral Vein, Percutaneous Approach

Introduction of Other Therapeutic Monoclonal Antibody into Peripheral Vein, Percutaneous Approach

Introduction of Radioactive Substance into Peripheral Vein, Percutaneous Approach

Introduction of Other Diagnostic Substance into Peripheral Vein, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Vein, Percutaneous Approach

Introduction of Platelet Inhibitor into Peripheral Vein, Percutaneous Approach

Introduction of Antiarrhythmic into Peripheral Vein, Percutaneous Approach

Introduction of Destructive Agent into Peripheral Vein, Percutaneous Approach

Introduction of Autologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach

Introduction of Nonautologous Pancreatic Islet Cells into Peripheral Vein, Percutaneous Approach

Introduction of Insulin into Peripheral Vein, Percutaneous Approach

Introduction of Human B-type Natriuretic Peptide into Peripheral Vein, Percutaneous Approach

Introduction of Other Hormone into Peripheral Vein, Percutaneous Approach

Introduction of Immunostimulator into Peripheral Vein, Percutaneous

Introduction of Immunosuppressive into Peripheral Vein, Percutaneous

Introduction of Vasopressor into Peripheral Vein, Percutaneous Approach

Introduction of High-dose Interleukin-2 into Central Vein, Open Approach

Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach

Introduction of Other Antineoplastic into Central Vein, Open Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach

Introduction of Clofarabine into Central Vein, Open Approach

Introduction of Recombinant Human-activated Protein C into Central Vein, Open

Introduction of Other Thrombolytic into Central Vein, Open Approach

Introduction of Oxazolidinones into Central Vein, Open Approach

Introduction of Other Anti-infective into Central Vein, Open Approach

Introduction of Anti-inflammatory into Central Vein, Open Approach

Introduction of Serum, Toxoid and Vaccine into Central Vein, Open Approach

Introduction of Nutritional Substance into Central Vein, Open Approach

Introduction of Electrolytic and Water Balance Substance into Central Vein, Open Approach

Introduction of Intracirculatory Anesthetic into Central Vein, Open Approach

Introduction of Other Therapeutic Substance into Central Vein, Open Approach

Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Open Approach

Introduction of Radioactive Substance into Central Vein, Open Approach

Introduction of Other Diagnostic Substance into Central Vein, Open Approach

Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Open Approach

Introduction of Platelet Inhibitor into Central Vein, Open Approach

Introduction of Antiarrhythmic into Central Vein, Open Approach

Introduction of Destructive Agent into Central Vein, Open Approach

Introduction of Insulin into Central Vein, Open Approach

Introduction of Human B-type Natriuretic Peptide into Central Vein, Open Approach

Introduction of Other Hormone into Central Vein, Open Approach

Introduction of Immunostimulator into Central Vein, Open

Introduction of Immunosuppressive into Central Vein, Open

Introduction of Vasopressor into Central Vein, Open Approach

Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach

Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach

Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach

Introduction of Clofarabine into Central Vein, Percutaneous Approach

Introduction of Recombinant Human-activated Protein C into Central Vein, Percutaneous

Introduction of Other Thrombolytic into Central Vein, Percutaneous Approach

Introduction of Oxazolidinones into Central Vein, Percutaneous Approach

Introduction of Other Anti-infective into Central Vein, Percutaneous Approach

Introduction of Anti-inflammatory into Central Vein, Percutaneous Approach

Introduction of Serum, Toxoid and Vaccine into Central Vein, Percutaneous Approach

Introduction of Nutritional Substance into Central Vein, Percutaneous Approach

Introduction of Electrolytic and Water Balance Substance into Central Vein, Percutaneous Approach

Introduction of Embryonic Stem Cells into Central Vein, Percutaneous Approach

Introduction of Intracirculatory Anesthetic into Central Vein, Percutaneous Approach

Introduction of Other Therapeutic Substance into Central Vein, Percutaneous Approach

Introduction of Blood Brain Barrier Disruption Substance into Central Vein, Percutaneous Approach

Introduction of Glucarpidase into Central Vein, Percutaneous Approach

Introduction of Other Therapeutic Monoclonal Antibody into Central Vein, Percutaneous Approach

Introduction of Radioactive Substance into Central Vein, Percutaneous Approach

Introduction of Other Diagnostic Substance into Central Vein, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Central Vein, Percutaneous Approach

Introduction of Platelet Inhibitor into Central Vein, Percutaneous Approach

Introduction of Antiarrhythmic into Central Vein, Percutaneous Approach

Introduction of Destructive Agent into Central Vein, Percutaneous Approach

Introduction of Insulin into Central Vein, Percutaneous Approach

Introduction of Human B-type Natriuretic Peptide into Central Vein, Percutaneous Approach

Introduction of Other Hormone into Central Vein, Percutaneous Approach

Introduction of Immunostimulator into Central Vein, Percutaneous

Introduction of Immunosuppressive into Central Vein, Percutaneous

Introduction of Vasopressor into Central Vein, Percutaneous Approach

Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach

Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach

Introduction of Other Antineoplastic into Peripheral Artery, Open Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach

Introduction of Clofarabine into Peripheral Artery, Open Approach

Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Open

Introduction of Other Thrombolytic into Peripheral Artery, Open Approach

Introduction of Oxazolidinones into Peripheral Artery, Open Approach

Introduction of Other Anti-infective into Peripheral Artery, Open Approach

Introduction of Anti-inflammatory into Peripheral Artery, Open Approach

Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Open Approach

Introduction of Nutritional Substance into Peripheral Artery, Open Approach

Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Open Approach

Introduction of Intracirculatory Anesthetic into Peripheral Artery, Open Approach

Introduction of Other Therapeutic Substance into Peripheral Artery, Open Approach

Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Open Approach

Introduction of Radioactive Substance into Peripheral Artery, Open Approach

Introduction of Other Diagnostic Substance into Peripheral Artery, Open Approach

Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Open Approach

Introduction of Platelet Inhibitor into Peripheral Artery, Open Approach

Introduction of Antiarrhythmic into Peripheral Artery, Open Approach

Introduction of Destructive Agent into Peripheral Artery, Open Approach

Introduction of Insulin into Peripheral Artery, Open Approach

Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Open Approach

Introduction of Other Hormone into Peripheral Artery, Open Approach

Introduction of Immunostimulator into Peripheral Artery, Open

Introduction of Immunosuppressive into Peripheral Artery, Open

Introduction of Vasopressor into Peripheral Artery, Open Approach

Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach

Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach

Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach

Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach

Introduction of Recombinant Human-activated Protein C into Peripheral Artery, Percutaneous

Introduction of Other Thrombolytic into Peripheral Artery, Percutaneous Approach

Introduction of Oxazolidinones into Peripheral Artery, Percutaneous Approach

Introduction of Other Anti-infective into Peripheral Artery, Percutaneous Approach

Introduction of Anti-inflammatory into Peripheral Artery, Percutaneous Approach

Introduction of Serum, Toxoid and Vaccine into Peripheral Artery, Percutaneous Approach

Introduction of Nutritional Substance into Peripheral Artery, Percutaneous Approach

Introduction of Electrolytic and Water Balance Substance into Peripheral Artery, Percutaneous Approach

Introduction of Intracirculatory Anesthetic into Peripheral Artery, Percutaneous Approach

Introduction of Other Therapeutic Substance into Peripheral Artery, Percutaneous Approach

Introduction of Blood Brain Barrier Disruption Substance into Peripheral Artery, Percutaneous Approach

Introduction of Radioactive Substance into Peripheral Artery, Percutaneous Approach

Introduction of Other Diagnostic Substance into Peripheral Artery, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Peripheral Artery, Percutaneous Approach

Introduction of Platelet Inhibitor into Peripheral Artery, Percutaneous Approach

Introduction of Antiarrhythmic into Peripheral Artery, Percutaneous Approach

Introduction of Destructive Agent into Peripheral Artery, Percutaneous Approach

Introduction of Insulin into Peripheral Artery, Percutaneous Approach

Introduction of Human B-type Natriuretic Peptide into Peripheral Artery, Percutaneous Approach

Introduction of Other Hormone into Peripheral Artery, Percutaneous Approach

Introduction of Immunostimulator into Peripheral Artery, Percutaneous

Introduction of Immunosuppressive into Peripheral Artery, Percutaneous

Introduction of Vasopressor into Peripheral Artery, Percutaneous Approach

Introduction of High-dose Interleukin-2 into Central Artery, Open Approach

Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach

Introduction of Other Antineoplastic into Central Artery, Open Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach

Introduction of Clofarabine into Central Artery, Open Approach

Introduction of Recombinant Human-activated Protein C into Central Artery, Open

Introduction of Other Thrombolytic into Central Artery, Open Approach

Introduction of Oxazolidinones into Central Artery, Open Approach

Introduction of Other Anti-infective into Central Artery, Open Approach

Introduction of Anti-inflammatory into Central Artery, Open Approach

Introduction of Serum, Toxoid and Vaccine into Central Artery, Open Approach

Introduction of Nutritional Substance into Central Artery, Open Approach

Introduction of Electrolytic and Water Balance Substance into Central Artery, Open Approach

Introduction of Intracirculatory Anesthetic into Central Artery, Open Approach

Introduction of Other Therapeutic Substance into Central Artery, Open Approach

Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Open Approach

Introduction of Radioactive Substance into Central Artery, Open Approach

Introduction of Other Diagnostic Substance into Central Artery, Open Approach

Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Open Approach

Introduction of Platelet Inhibitor into Central Artery, Open Approach

Introduction of Antiarrhythmic into Central Artery, Open Approach

Introduction of Destructive Agent into Central Artery, Open Approach

Introduction of Insulin into Central Artery, Open Approach

Introduction of Human B-type Natriuretic Peptide into Central Artery, Open Approach

Introduction of Other Hormone into Central Artery, Open Approach

Introduction of Immunostimulator into Central Artery, Open

Introduction of Immunosuppressive into Central Artery, Open

Introduction of Vasopressor into Central Artery, Open Approach

Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach

Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach

Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach

Introduction of Clofarabine into Central Artery, Percutaneous Approach

Introduction of Recombinant Human-activated Protein C into Central Artery, Percutaneous

Introduction of Other Thrombolytic into Central Artery, Percutaneous Approach

Introduction of Oxazolidinones into Central Artery, Percutaneous Approach

Introduction of Other Anti-infective into Central Artery, Percutaneous Approach

Introduction of Anti-inflammatory into Central Artery, Percutaneous Approach

Introduction of Serum, Toxoid and Vaccine into Central Artery, Percutaneous Approach

Introduction of Nutritional Substance into Central Artery, Percutaneous Approach

Introduction of Electrolytic and Water Balance Substance into Central Artery, Percutaneous Approach

Introduction of Intracirculatory Anesthetic into Central Artery, Percutaneous Approach

Introduction of Other Therapeutic Substance into Central Artery, Percutaneous Approach

Introduction of Blood Brain Barrier Disruption Substance into Central Artery, Percutaneous Approach

Introduction of Radioactive Substance into Central Artery, Percutaneous Approach

Introduction of Other Diagnostic Substance into Central Artery, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Central Artery, Percutaneous Approach

Introduction of Platelet Inhibitor into Central Artery, Percutaneous Approach

Introduction of Antiarrhythmic into Central Artery, Percutaneous Approach

Introduction of Destructive Agent into Central Artery, Percutaneous Approach

Introduction of Insulin into Central Artery, Percutaneous Approach

Introduction of Human B-type Natriuretic Peptide into Central Artery, Percutaneous Approach

Introduction of Other Hormone into Central Artery, Percutaneous Approach

Introduction of Immunostimulator into Central Artery, Percutaneous

Introduction of Immunosuppressive into Central Artery, Percutaneous

Introduction of Vasopressor into Central Artery, Percutaneous Approach

Introduction of Recombinant Human-activated Protein C into Coronary Artery, Open

Introduction of Other Thrombolytic into Coronary Artery, Open Approach

Introduction of Other Therapeutic Substance into Coronary Artery, Open Approach

Introduction of Other Diagnostic Substance into Coronary Artery, Open Approach

Introduction of Platelet Inhibitor into Coronary Artery, Open Approach

Introduction of Recombinant Human-activated Protein C into Coronary Artery, Percutaneous

Introduction of Other Thrombolytic into Coronary Artery, Percutaneous Approach

Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Approach

Introduction of Other Diagnostic Substance into Coronary Artery, Percutaneous Approach

Introduction of Platelet Inhibitor into Coronary Artery, Percutaneous Approach

Introduction of Other Therapeutic Substance into Coronary Artery, Percutaneous Endoscopic Approach

Introduction of Recombinant Human-activated Protein C into Heart, Open

Introduction of Other Thrombolytic into Heart, Open Approach

Introduction of Other Therapeutic Substance into Heart, Open Approach

Introduction of Other Diagnostic Substance into Heart, Open Approach

Introduction of Platelet Inhibitor into Heart, Open Approach

Introduction of Recombinant Human-activated Protein C into Heart, Percutaneous

Introduction of Other Thrombolytic into Heart, Percutaneous Approach

Introduction of Other Therapeutic Substance into Heart, Percutaneous Approach

Introduction of Other Diagnostic Substance into Heart, Percutaneous Approach

Introduction of Platelet Inhibitor into Heart, Percutaneous Approach

Introduction of Other Therapeutic Substance into Heart, Percutaneous Endoscopic Approach

Introduction of Other Antineoplastic into Nose, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach

Introduction of Oxazolidinones into Nose, Percutaneous Approach

Introduction of Other Anti-infective into Nose, Percutaneous Approach

Introduction of Anti-inflammatory into Nose, Percutaneous Approach

Introduction of Serum, Toxoid and Vaccine into Nose, Percutaneous Approach

Introduction of Anesthetic Agent into Nose, Percutaneous Approach

Introduction of Other Therapeutic Substance into Nose, Percutaneous Approach

Introduction of Radioactive Substance into Nose, Percutaneous Approach

Introduction of Other Diagnostic Substance into Nose, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Nose, Percutaneous Approach

Introduction of Destructive Agent into Nose, Percutaneous Approach

Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening

Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening

Introduction of Oxazolidinones into Nose, Via Natural or Artificial Opening

Introduction of Other Anti-infective into Nose, Via Natural or Artificial Opening

Introduction of Anti-inflammatory into Nose, Via Natural or Artificial Opening

Introduction of Serum, Toxoid and Vaccine into Nose, Via Natural or Artificial Opening

Introduction of Anesthetic Agent into Nose, Via Natural or Artificial Opening

Introduction of Other Therapeutic Substance into Nose, Via Natural or Artificial Opening

Introduction of Radioactive Substance into Nose, Via Natural or Artificial Opening

Introduction of Other Diagnostic Substance into Nose, Via Natural or Artificial Opening

Introduction of Analgesics, Hypnotics, Sedatives into Nose, Via Natural or Artificial Opening

Introduction of Destructive Agent into Nose, Via Natural or Artificial Opening

Introduction of Other Antineoplastic into Nose, External Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach

Introduction of Oxazolidinones into Nose, External Approach

Introduction of Other Anti-infective into Nose, External Approach

Introduction of Anti-inflammatory into Nose, External Approach

Introduction of Serum, Toxoid and Vaccine into Nose, External Approach

Introduction of Anesthetic Agent into Nose, External Approach

Introduction of Other Therapeutic Substance into Nose, External Approach

Introduction of Radioactive Substance into Nose, External Approach

Introduction of Other Diagnostic Substance into Nose, External Approach

Introduction of Analgesics, Hypnotics, Sedatives into Nose, External Approach

Introduction of Destructive Agent into Nose, External Approach

Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach

Introduction of Other Therapeutic Substance into Bone Marrow, Percutaneous Approach

Introduction of Liquid Brachytherapy Radioisotope into Ear, Percutaneous Approach

Introduction of Other Antineoplastic into Ear, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach

Introduction of Oxazolidinones into Ear, Percutaneous Approach

Introduction of Other Anti-infective into Ear, Percutaneous Approach

Introduction of Anti-inflammatory into Ear, Percutaneous Approach

Introduction of Anesthetic Agent into Ear, Percutaneous Approach

Introduction of Other Therapeutic Substance into Ear, Percutaneous Approach

Introduction of Radioactive Substance into Ear, Percutaneous Approach

Introduction of Other Diagnostic Substance into Ear, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Ear, Percutaneous Approach

Introduction of Destructive Agent into Ear, Percutaneous Approach

Introduction of Liquid Brachytherapy Radioisotope into Ear, Via Natural or Artificial Opening

Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening

Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening

Introduction of Oxazolidinones into Ear, Via Natural or Artificial Opening

Introduction of Other Anti-infective into Ear, Via Natural or Artificial Opening

Introduction of Anti-inflammatory into Ear, Via Natural or Artificial Opening

Introduction of Anesthetic Agent into Ear, Via Natural or Artificial Opening

Introduction of Other Therapeutic Substance into Ear, Via Natural or Artificial Opening

Introduction of Radioactive Substance into Ear, Via Natural or Artificial Opening

Introduction of Other Diagnostic Substance into Ear, Via Natural or Artificial Opening

Introduction of Analgesics, Hypnotics, Sedatives into Ear, Via Natural or Artificial Opening

Introduction of Destructive Agent into Ear, Via Natural or Artificial Opening

Introduction of Liquid Brachytherapy Radioisotope into Ear, External Approach

Introduction of Other Antineoplastic into Ear, External Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach

Introduction of Oxazolidinones into Ear, External Approach

Introduction of Other Anti-infective into Ear, External Approach

Introduction of Anti-inflammatory into Ear, External Approach

Introduction of Anesthetic Agent into Ear, External Approach

Introduction of Other Therapeutic Substance into Ear, External Approach

Introduction of Radioactive Substance into Ear, External Approach

Introduction of Other Diagnostic Substance into Ear, External Approach

Introduction of Analgesics, Hypnotics, Sedatives into Ear, External Approach

Introduction of Destructive Agent into Ear, External Approach

Introduction of Liquid Brachytherapy Radioisotope into Eye, Percutaneous Approach

Introduction of Other Antineoplastic into Eye, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach

Introduction of Oxazolidinones into Eye, Percutaneous Approach

Introduction of Other Anti-infective into Eye, Percutaneous Approach

Introduction of Anti-inflammatory into Eye, Percutaneous Approach

Introduction of Anesthetic Agent into Eye, Percutaneous Approach

Introduction of Other Therapeutic Substance into Eye, Percutaneous Approach

Introduction of Radioactive Substance into Eye, Percutaneous Approach

Introduction of Other Diagnostic Substance into Eye, Percutaneous Approach

Introduction of Pigment into Eye, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Eye, Percutaneous Approach

Introduction of Other Gas into Eye, Percutaneous Approach

Introduction of Destructive Agent into Eye, Percutaneous Approach

Introduction of Liquid Brachytherapy Radioisotope into Eye, Via Natural or Artificial Opening

Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening

Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening

Introduction of Oxazolidinones into Eye, Via Natural or Artificial Opening

Introduction of Other Anti-infective into Eye, Via Natural or Artificial Opening

Introduction of Anti-inflammatory into Eye, Via Natural or Artificial Opening

Introduction of Anesthetic Agent into Eye, Via Natural or Artificial Opening

Introduction of Other Therapeutic Substance into Eye, Via Natural or Artificial Opening

Introduction of Radioactive Substance into Eye, Via Natural or Artificial Opening

Introduction of Other Diagnostic Substance into Eye, Via Natural or Artificial Opening

Introduction of Pigment into Eye, Via Natural or Artificial Opening

Introduction of Analgesics, Hypnotics, Sedatives into Eye, Via Natural or Artificial Opening

Introduction of Other Gas into Eye, Via Natural or Artificial Opening

Introduction of Destructive Agent into Eye, Via Natural or Artificial Opening

Introduction of Liquid Brachytherapy Radioisotope into Eye, External Approach

Introduction of Other Antineoplastic into Eye, External Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach

Introduction of Oxazolidinones into Eye, External Approach

Introduction of Other Anti-infective into Eye, External Approach

Introduction of Anti-inflammatory into Eye, External Approach

Introduction of Anesthetic Agent into Eye, External Approach

Introduction of Other Therapeutic Substance into Eye, External Approach

Introduction of Radioactive Substance into Eye, External Approach

Introduction of Other Diagnostic Substance into Eye, External Approach

Introduction of Pigment into Eye, External Approach

Introduction of Analgesics, Hypnotics, Sedatives into Eye, External Approach

Introduction of Other Gas into Eye, External Approach

Introduction of Destructive Agent into Eye, External Approach

Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Percutaneous Approach

Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach

Introduction of Oxazolidinones into Mouth and Pharynx, Percutaneous Approach

Introduction of Other Anti-infective into Mouth and Pharynx, Percutaneous Approach

Introduction of Anti-inflammatory into Mouth and Pharynx, Percutaneous Approach

Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Percutaneous Approach

Introduction of Nutritional Substance into Mouth and Pharynx, Percutaneous Approach

Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Percutaneous Approach

Introduction of Anesthetic Agent into Mouth and Pharynx, Percutaneous Approach

Introduction of Other Therapeutic Substance into Mouth and Pharynx, Percutaneous Approach

Introduction of Radioactive Substance into Mouth and Pharynx, Percutaneous Approach

Introduction of Other Diagnostic Substance into Mouth and Pharynx, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Percutaneous Approach

Introduction of Antiarrhythmic into Mouth and Pharynx, Percutaneous Approach

Introduction of Destructive Agent into Mouth and Pharynx, Percutaneous Approach

Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Oxazolidinones into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Other Anti-infective into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Anti-inflammatory into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Nutritional Substance into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Anesthetic Agent into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Other Therapeutic Substance into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Radioactive Substance into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Other Diagnostic Substance into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Antiarrhythmic into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Destructive Agent into Mouth and Pharynx, Via Natural or Artificial Opening

Introduction of Liquid Brachytherapy Radioisotope into Mouth and Pharynx, External Approach

Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach

Introduction of Oxazolidinones into Mouth and Pharynx, External Approach

Introduction of Other Anti-infective into Mouth and Pharynx, External Approach

Introduction of Anti-inflammatory into Mouth and Pharynx, External Approach

Introduction of Serum, Toxoid and Vaccine into Mouth and Pharynx, External Approach

Introduction of Nutritional Substance into Mouth and Pharynx, External Approach

Introduction of Electrolytic and Water Balance Substance into Mouth and Pharynx, External Approach

Introduction of Anesthetic Agent into Mouth and Pharynx, External Approach

Introduction of Other Therapeutic Substance into Mouth and Pharynx, External Approach

Introduction of Radioactive Substance into Mouth and Pharynx, External Approach

Introduction of Other Diagnostic Substance into Mouth and Pharynx, External Approach

Introduction of Analgesics, Hypnotics, Sedatives into Mouth and Pharynx, External Approach

Introduction of Antiarrhythmic into Mouth and Pharynx, External Approach

Introduction of Destructive Agent into Mouth and Pharynx, External Approach

Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Percutaneous Approach

Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach

Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach

Introduction of Oxazolidinones into Products of Conception, Percutaneous Approach

Introduction of Other Anti-infective into Products of Conception, Percutaneous Approach

Introduction of Anti-inflammatory into Products of Conception, Percutaneous Approach

Introduction of Nutritional Substance into Products of Conception, Percutaneous Approach

Introduction of Electrolytic and Water Balance Substance into Products of Conception, Percutaneous Approach

Introduction of Anesthetic Agent into Products of Conception, Percutaneous Approach

Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Approach

Introduction of Radioactive Substance into Products of Conception, Percutaneous Approach

Introduction of Other Diagnostic Substance into Products of Conception, Percutaneous Approach

Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Percutaneous Approach

Introduction of Other Gas into Products of Conception, Percutaneous Approach

Introduction of Destructive Agent into Products of Conception, Percutaneous Approach

Introduction of Other Therapeutic Substance into Products of Conception, Percutaneous Endoscopic Approach

Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening

Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening

Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening

Introduction of Oxazolidinones into Products of Conception, Via Natural or Artificial Opening

Introduction of Other Anti-infective into Products of Conception, Via Natural or Artificial Opening

Introduction of Anti-inflammatory into Products of Conception, Via Natural or Artificial Opening

Introduction of Nutritional Substance into Products of Conception, Via Natural or Artificial Opening

Introduction of Electrolytic and Water Balance Substance into Products of Conception, Via Natural or Artificial Opening

Introduction of Anesthetic Agent into Products of Conception, Via Natural or Artificial Opening

Introduction of Other Therapeutic Substance into Products of Conception, Via Natural or Artificial Opening

Introduction of Radioactive Substance into Products of Conception, Via Natural or Artificial Opening

Introduction of Other Diagnostic Substance into Products of Conception, Via Natural or Artificial Opening

Introduction of Analgesics, Hypnotics, Sedatives into Products of Conception, Via Natural or Artificial Opening

Introduction of Other Gas into Products of Conception, Via Natural or Artificial Opening

Introduction of Destructive Agent into Products of Conception, Via Natural or Artificial Opening

Introduction of Liquid Brachytherapy Radioisotope into Products of Conception, Via Natural or Artificial Opening Endoscopic

Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic